secwatch.observer — SEC 8-K summary
======================================

Issuer:     Natera, Inc. (NTRA)
CIK:        0001604821
Form:       8-K
Filed at:   2023-02-28T23:59:59+00:00
Accession:  0001104659-23-026715
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Natera Q4 revenue $217.3M (+25.6% YoY); net loss $142.6M; guides 2023 rev $980M-$1B
--------------------------------------------------------------------------------

- Q4 total revenue $217.3M (+25.6% YoY); product revenue $212.9M (+28.2%); tests processed 559,700 (+27.6%).
- Full-year 2022 revenue $820.2M (+31.1% YoY); net loss $547.8M ($5.57/diluted) vs $471.7M ($5.21) in 2021.
- Oncology tests 196,000 in 2022 (+158% YoY); 40 peer-reviewed studies for Signatera published.
- 2023 guidance: revenue $980M-$1B; gross margin 41%-44%; net cash consumption $300M-$325M.
- Appointed Ruth Williams-Brinkley to board effective March 2, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604821/000110465923026715/0001104659-23-026715-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604821/000110465923026715/tm238033d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-026715

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer